A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Melphalan (Primary)
- Indications Liver metastases; Uveal melanoma
- Focus Registrational; Therapeutic Use
- Acronyms FOCUS
- Sponsors Delcath Systems
- 11 Nov 2016 According to Delcath media release, company has expanded this trial to include 10 new research centers in the U.S. and Europe.
- 18 Oct 2016 According to a Delcath Systems media release, the company is on track to complete enrollment in mid-2018 with the potential for a pre-specified interim analysis around the end of 2017.
- 20 Jan 2016 Status changed from planning to recruiting, according to a Delcath media release.